A specialty subsidiary of Innoviva and the Global Antibiotic Research & Development Partnership conducted the research into the pathogen deemed a priority by the World Health Organization.
GARDP called the clinical trial “pivotal” and “unprecedented” as antimicrobial resistance rises.
“Study investigators found that oral zoliflodacin demonstrated statistical non-inferiority of microbiological cure at the urogenital site when compared to treatment with intramuscular injection of ceftriaxone and oral azithromycin, a current global standard of care regimen,” the organization said in a news release.
If zoliflodacin is approved, it will be the first new gonorrhea antibiotic in decades.
Gonorrhea is the third-most common sexually transmitted infection, and it affects 82 million people per year, according to GARDP.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.